KPV 5mg

KPV (5mg) – Research Overview

KPV is a research-grade tripeptide (Lys-Pro-Val) derived from the C-terminal sequence of alpha-melanocyte stimulating hormone (alpha-MSH). As a naturally occurring fragment of alpha-MSH, KPV has been studied in preclinical research models examining intracellular signaling pathways and cytokine regulation mechanisms.

What the Research Shows

KPV is studied for its interactions with intracellular inflammatory signaling pathways. Research has documented KPV’s ability to cross cell membranes and interact with intracellular targets independently of surface receptor binding, including documented effects on NF-kB p65 nuclear translocation in intestinal epithelial cell models. This cell-penetrating property distinguishes KPV from many other anti-inflammatory peptides that act exclusively through surface receptors. Preclinical models in mucosal tissue have examined KPV’s effects on cytokine production, particularly IL-8 and TNF-alpha, in inflammatory conditions.

As of 2026, KPV is not approved by the FDA for human or veterinary therapeutic use. Human clinical trial data is absent. All findings are preclinical.

Quality Documentation

• 99%+ purity — HPLC and Mass Spectrometry verified
• 5mg KPV lyophilized powder
• Batch-specific COA included with every order
• USA tested and fulfilled

For laboratory research purposes only. Not for human or veterinary consumption.